Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Class A common stock, par value $0.00001 per share
-
Shares outstanding
-
111M
-
Number of holders
-
278
-
Total 13F shares, excl. options
-
81.7M
-
Shares change
-
+3.17M
-
Total reported value, excl. options
-
$6.21B
-
Value change
-
-$97.6M
-
Put/Call ratio
-
0.52
-
Number of buys
-
162
-
Number of sells
-
-161
-
Price
-
$76.07
Significant Holders of 10x Genomics, Inc. - Class A common stock, par value $0.00001 per share (TXG) as of Q1 2022
391 filings reported holding TXG - 10x Genomics, Inc. - Class A common stock, par value $0.00001 per share as of Q1 2022.
10x Genomics, Inc. - Class A common stock, par value $0.00001 per share (TXG) has 278 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.7M shares
of 111M outstanding shares and own 73.41% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (9.3M shares), BlackRock Inc. (9.16M shares), VANGUARD GROUP INC (7.73M shares), BAILLIE GIFFORD & CO (7.36M shares), FMR LLC (4.13M shares), ARK Investment Management LLC (3.39M shares), SANDS CAPITAL MANAGEMENT, LLC (3.2M shares), 12 West Capital Management LP (2.52M shares), Foresite Capital Management II, LLC (1.75M shares), and STATE STREET CORP (1.68M shares).
This table shows the top 278 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.